Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sunitinib with regorafenib falls short for metastatic GIST

Serrano C et al. ASCO 2018 Abstract 11510.

Key clinical point: The strategy of rapid alteration of drugs to overcome imatinib resistance mutation in gastrointestinal stromal tumor (GIST) is feasible but was ineffective.

Major finding: There were no objective responses among 12 patients treated continuously with 3 days of sunitinib (Sutent) followed by 4 days of regorafenib (Stivarga). Although four patients had stable disease in the short term, in each case the disease progressed within 16 weeks.

Study details: Phase Ib clinical trial in 12 patients with heavily pre-treated metastatic GIST.

Disclosures: The study was supported by an ASCO Young Investigator Award, Pfizer, and Bayer. Dr. Serrano disclosed honoraria from Bayer, a consulting or advisory role for Deciphera, research funding from Bayer and Deciphera, and travel accommodations and expenses from Pfizer.

Source: Serrano C et al. ASCO 2018 Abstract 11510.


Serrano C et al. ASCO 2018 Abstract 11510.

This Week's Must Reads

Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018

Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142

Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits

The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32

Must Reads in Sarcoma & GIST

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165.

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406.

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.